Trump Signals Federal Cannabis Rescheduling Push

President Trump has signaled his administration will pursue federal marijuana rescheduling, marking a potential acceleration of cannabis regulatory reform that could reshape the $30 billion U.S. cannabis market. The move builds on the Biden administration's ongoing DEA review process, which has stalled for months despite initial momentum toward moving cannabis from Schedule I to Schedule III under the Controlled Substances Act.

Rescheduling would deliver immediate tax relief to cannabis operators currently barred from standard business deductions under Section 280E. Multi-state operators like Curaleaf (CURA), Green Thumb Industries (GTII), and Trulieve (TCNNF) could see operating margins expand by 15-20 percentage points, translating to hundreds of millions in additional cash flow across the sector. The tax burden has particularly pressured smaller operators struggling with profitability in oversupplied markets like California and Colorado.

The regulatory shift would also unlock institutional capital that remains largely sidelined due to federal prohibition. Major banks, pension funds, and institutional investors have avoided cannabis investments despite strong fundamentals at leading operators. Rescheduling stops short of full legalization but removes significant compliance barriers that have fragmented the industry across state lines.

Trump's position represents a notable evolution from his previous administration's cannabis stance, reflecting growing political consensus around reform. Thirty-eight states now permit medical cannabis while 21 allow adult-use programs, creating a patchwork of regulations that rescheduling would begin to standardize. The move could also pressure Congress toward broader banking reform through the SAFE Banking Act, which has repeatedly stalled despite bipartisan support.

The timeline remains uncertain as rescheduling requires extensive DEA review and public comment periods. However, Trump's explicit support could expedite a process that typically spans 12-18 months. Cannabis stocks have rallied intermittently on rescheduling speculation over the past two years, but sustained momentum depends on concrete regulatory action rather than political positioning. The sector trades at significant discounts to traditional consumer goods companies despite comparable growth rates and improving profitability metrics.